Literature DB >> 11301811

Influenza vaccine: issues and opportunities.

K M Neuzil1, M R Griffin, W Schaffner.   

Abstract

Several recent developments offer opportunities to improve the diagnosis, treatment, and prevention of influenza. Rapid diagnostic tests assist in selecting patients for antiviral therapy and avoid some antibiotic use. The neuraminidase inhibitors now offer therapeutic options with potentially fewer side effects than the traditional drugs, albeit at greater cost. Inactivated influenza vaccine is now recommended annually for all persons aged 50 and older and younger adults and children (aged 6 months and older) who have underlying risk factors for the severe complications of influenza. This includes pregnant women who are in their second or third trimesters during influenza season.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11301811     DOI: 10.1016/s0891-5520(05)70271-3

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  2 in total

1.  [Immunisation: leaps into the future. The flu virus and syncytial respiratory virus: strategies for active immunisation].

Authors:  G Mato Chaín; A Mariano Lázaro; G Rodríguez Caravaca; J Fereres Castiel
Journal:  Aten Primaria       Date:  2002-09-15       Impact factor: 1.137

Review 2.  Influenza vaccinations: who needs them and when?

Authors:  Eelko Hak; Arno W Hoes; Theo J M Verheij
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.